Form 4: SpringWorks Therapeutics Officer Disposes of Equity Holdings Following Merger Completion

Daniel Pichl, Chief People Officer of SpringWorks Therapeutics, Inc., disposed of all his beneficial ownership in the company's common stock, restricted stock units, performance share units, and stock options as a result of the company's acquisition by Merck KGaA, Darmstadt, Germany.

Summary

• Daniel Pichl, Chief People Officer of SpringWorks Therapeutics, Inc. (SWTX), reported the disposition of all his beneficial ownership in the company's securities.
• The disposition occurred on July 1, 2025, coinciding with the effective time of the merger between SpringWorks Therapeutics, Inc. and EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany.
• Under the terms of the Merger Agreement, each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash.
• Pichl disposed of 50,762 shares of common stock, which included 34,780 shares underlying restricted stock units (RSUs).
• He also disposed of 16,023 performance share units (PSUs).
• Additionally, 239,135 stock options were disposed of, with exercise prices ranging from $27.64 to $43.1.
• Outstanding RSUs and PSUs, whether vested or unvested, were converted into cash-based awards based on the $47.00 merger consideration, generally retaining their original vesting schedules, with a special provision for 50% of unvested tranches to vest on the nine-month anniversary of the closing date, subject to continued employment.
• Vested and unvested stock options were converted into cash based on the difference between the $47.00 merger consideration and their respective exercise prices, also generally retaining original vesting schedules with a similar nine-month anniversary vesting provision for unvested tranches.
• Any stock options with an exercise price greater than $47.00 were cancelled for no consideration.

Sentiment

Score: 7

Explanation: The sentiment is positive as the merger successfully closed, providing a cash exit for shareholders and converting equity awards into cash-based equivalents, which is a favorable outcome for the reporting person's holdings, despite the cancellation of out-of-the-money options.

Positives

• The merger provided a clear cash exit for shareholders and equity holders at a fixed price of $47.00 per share.
• Equity awards (RSUs, PSUs, and in-the-money options) were converted into cash-based awards, providing liquidity or future cash payments based on the merger consideration.
• Unvested equity awards generally retain their original vesting terms, with an accelerated vesting of 50% of each then-unvested tranche on the nine-month anniversary of the merger closing, subject to continued employment, providing a retention incentive and partial accelerated liquidity for the reporting person.

Negatives

• Stock options with an exercise price greater than $47.00 were cancelled for no consideration, resulting in a loss of potential value for those specific awards.
• The disposition of all equity holdings means the reporting person no longer has direct equity upside in SpringWorks Therapeutics, Inc., as it is now a wholly owned subsidiary of Merck KGaA.

Future Outlook

The document indicates that unvested cash-based RSU and option awards will generally vest in accordance with their original terms, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger closing date, subject to the holder's continued employment with Parent.

Industry Context

This Form 4 filing reflects the final stages of a significant M&A transaction in the biotechnology and pharmaceutical sector, where a smaller, publicly traded company (SpringWorks Therapeutics) is acquired by a larger global pharmaceutical entity (Merck KGaA). Such acquisitions are common in the industry, driven by strategic portfolio expansion, access to new drug pipelines, or market consolidation.

Comparison to Industry Standards

• The conversion of equity awards into cash-based awards with continued vesting, particularly the accelerated vesting of a portion of unvested tranches, is a common practice in M&A transactions to retain key personnel post-acquisition.
• The cancellation of out-of-the-money options for no consideration is standard practice in mergers where the per-share consideration is less than the option's exercise price.

Stakeholder Impact

• Shareholders: Received $47.00 per share in cash for their common stock, concluding their investment in SpringWorks Therapeutics.
• Employees (including Daniel Pichl): Equity awards were converted into cash-based awards, providing liquidity and retention incentives through continued vesting, subject to employment with the acquiring entity.
• Merck KGaA: Successfully acquired SpringWorks Therapeutics, integrating its assets and personnel.

Next Steps

• The reporting person's remaining unvested cash-based RSU and option awards will continue to vest according to their modified terms, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger closing date, subject to continued employment.

Key Dates

Recommendation

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, SEC Form 4, Insider Trading, Equity Disposition, Restricted Stock Units, Performance Share Units, Stock Options, Cash Consideration, Corporate Governance, Executive Compensation